BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
Clinical - Phase III
KEYTRUDA (Pembrolizumab), Merck & Co. (MRK)’s Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival And Overall Response Rate Compared To Ipilimumab An Anti-CTLA-4 Therapy 4/20/2015
Full Data On Baxter International (BAX)’s Investigational Recombinant Treatment BAX 111 Supports Potential Role To Treat Von Willebrand Disease 4/20/2015
Cyclacel Pharmaceuticals, Inc. (CYCC)'s Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeutic Potential And Synergy With Other Anti-Cancer Compounds 4/20/2015
MediWound (MDWD) Initiates U.S. Phase 3 Trial With NexoBrid To Treat Severe Burns 4/20/2015
Argos Therapeutics, Inc. (ARGS) To Present Update On Pivotal Phase 3 ADAPT Clinical Trial During 2015 ASCO Annual Meeting 4/20/2015
SAGE Therapeutics Announces First Patient Treated Under Phase 3 Expanded Access Protocol To Evaluate SAGE-547 In Patients With Super-Refractory Status Epilepticus 4/20/2015
Onconova Therapeutics Inc. (ONTX) Submits Pivotal Clinical Trial Protocol For IV Rigosertib In Higher-Risk Myelodysplastic Syndromes To FDA And European Medicines Agency 4/20/2015
Data Presented At AACR Demonstrate Peregrine Pharmaceuticals, Inc. (PPHM)' Bavituximab Induces Immune Activation In PD-L1 Negative NSCLC Tumors 4/20/2015
Eli Lilly (LLY)'s Ixekizumab Met Primary Endpoint In A Phase 3 Study Investigating The Treatment Of Psoriatic Arthritis 4/20/2015
Eli Lilly (LLY)'s Ixekizumab Succeeds in Late-Stage Study, Meets Primary Endpoint 4/20/2015
Baxter International (BAX)'s Bleeding Disorder Drug Delivers 100% Success Rate in Late-Stage Study 4/20/2015
Pembrolizumab, Merck & Co. (MRK)'s Investigational Anti PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival And Overall Response Rate Compared To Ipilimumab, An Anti-CTLA-4 Therapy, In A Phase 3 Study Of Patients With Advanced Melanoma 4/20/2015
Merz Neurosciences To Present Key Clinical Data At The Annual Meeting Of The American Academy of Neurology 4/20/2015
Bio Products Laboratory, Ltd. Announces Results From Phase III Registration Study Of Its Factor X Coagulation Product 4/20/2015
Global Strategic Partners Merck KGaA (MKGAF.PK), Darmstadt, Germany, And Pfizer (PFE) nitiate Phase III Study With Avelumab* In Patients With Stage IIIb/IV Non-Small Cell Lung Cancer 4/20/2015
Ampio Pharmaceuticals, Inc. (AMPE) Shares Decimated on Failed Trial Results 4/20/2015
H. Lundbeck A/S (LUN.CO) and Otsuka America Pharmaceutical, Inc. Release: Results Of Phase III Study Of Brexpiprazole In Adult Patients With Schizophrenia Published In American Journal Of Psychiatry 4/17/2015
MedDay Announces Its Pivotal Phase III Study Of MD1003 In Patients With Progressive Multiple Sclerosis Meets Primary Endpoint 4/17/2015
Full Data On Baxter International (BAX)’s Investigational Recombinant Treatment BAX 111 Supports Potential Role To Treat Von Willebrand Disease 4/17/2015
Bristol-Myers Squibb (BMY) Soars After Halting Study Early As Opdivo Aces Test Again 4/17/2015
Investors Suddenly Interested in Synta (SNTA) and Its Upcoming Cancer Data 4/17/2015
Ipsen (IPN.PA), Active Biotech AB (BTPC) Plummet As Prostate Cancer Drug Flunks Late-Stage Trial 4/17/2015
Pfizer (PFE) Beams As Cancer Drug Efficacy Stops Trial Early and Analysts Predict Game Changer 4/17/2015
Galena Biopharma  (GALE) Completes Over-Enrollment Of Neuvax (Nelipepimut-S) Phase 3 PRESENT Clinical Trial 4/16/2015
ZS Pharma (ZSPH) Announces Publications In Peer-Reviewed Medical Journals 4/16/2015
Peregrine Pharmaceuticals, Inc. (PPHM) Announces Three Abstracts Accepted For Presentation At American Association for Cancer Research 2015 Annual Meeting 4/16/2015
AEterna Zentaris (AEZS) Files Additional Patent Application To Strengthen IP Protection Of Zoptarelin Doxorubicin 4/16/2015
Adamis (ADMP) Pharmaceuticals Announces Positive Clinical Study Results For Its Albuterol (Salbutamol) HFA Product 4/16/2015
RegeneRx JV Retains Ora, Inc. To Conduct Phase 3 Trial For NK And Phase 2b/3 Trial For Dry Eye Syndrome In U.S. 4/16/2015
AbbVie (ABBV)'s Investigational Chronic Hepatitis C Treatment Granted Priority Review In Japan 4/16/2015
TRANSGENE (ENX:TNG): Agreement With FDA Announced For Special Protocol Assessment For Upcoming Phase 3 Pexa-Vec Trial In Advanced Liver Cancer 4/16/2015
SillaJen Announces Agreement With The FDA For A Special Protocol Assessment For Upcoming Phase 3 Pexa-Vec Trial In Advanced Liver Cancer 4/16/2015
Provectus Biopharmaceuticals Inc. Opens Patient Enrollment; Begins Phase 3 International FDA Comparative Clinical Trial Of PV-10 For Melanoma 4/16/2015
Roche (RHHBY) Says 11 Late-Stage Cancer Drugs Will Enter Trials in 2015 4/15/2015
Pfizer (PFE) Announces Paloma-3 Trial For Ibrance® (Palbociclib) Stopped Early Due To Efficacy Seen In Patients With Hr+, Her2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine Therapy 4/15/2015
Ocular Therapeutix (OCUL) Stock Caves After Eye Pain Drug Flunks Pivotal Trial 4/15/2015
Heart Metabolics Limited And FDA Reach Agreement On Special Protocol Assessment For Single Phase 3 Trial Of Perhexiline In Hypertrophic Cardiomyopathy 4/15/2015
CytoTools: Recruitment Of Patients Now Complete For European Studies On Diabetic Foot (DFU) And Ulcus Cruris (VLU) Indications 4/15/2015
Oncobiologics Inc. Announces Completion Of Clinical Dosing For bevacizumab (Avastin biosimilar) Candidate 4/15/2015
Phase III Trial Of The Merck & Co. (MRK) And NewLink Genetics Investigational Ebola Vaccine Initiated In Sierra Leone 4/15/2015
Heart Metabolics And FDA Reach Agreement On Special Protocol Assessment For Single Phase 3 Trial Of Perhexiline In Hypertrophic Cardiomyopathy 4/15/2015
Soligenix (SNGX) Announces FDA Protocol Clearance Of Pivotal Phase 3 Clinical Trial Of SGX203 In Pediatric Crohn's Disease 4/14/2015
Catalyst Pharmaceuticals (CPRX) Announces Oral Presentation Of Firdapse Phase 3 Trial Data At American Academy of Neurology Annual Meeting (AAN) 4/14/2015
Bayer HealthCare (BAY) Devises Phase III Plans for Top Prospect 4/14/2015
AEterna Zentaris (AEZS) Announces Plans To Initiate Phase 3 Study Of Macrilen In AGHD Following Successful Meeting With FDA 4/13/2015
Angionetics Initial Equity Funding To Advance As Independent Company To Develop And Commercialize Phase 3 Generx Gene Therapy Product Candidate 4/13/2015
Neothetics Initiates Pivotal Phase 3 Clinical Trials For LIPO-202, The First Non-Invasive Injectable Drug Candidate For Reduction Of Subcutaneous Abdominal Fat 4/13/2015
UK’s Aintree University Hospital Joins CEL-SCI (CVM)’s Phase III Head And Neck Cancer Trial 4/13/2015
Onxeo Announces 6th Positive DSMB Recommendation For Livatag Relive Study In HCC 4/13/2015
DBV Tech Nabs FDA Breakthrough Status for Peanut Allergy Patch 4/13/2015
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Shows That Health-Related Quality-Of-Life Is Higher In ABSSSI Patients Deemed Cured Vs Improved After End Of Treatment 4/10/2015
Cesca Therapeutics Management Provides Update On Clinical Trials For Critical Limb Ischemia ("CLI") And Acute Myocardial Infarction ("AMI") 4/10/2015
Adamas Pharmaceuticals (ADMS) Receives Orphan Drug Designation For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia Associated With Parkinson's Disease 4/10/2015
Lipocine Inc. (LPCN) Announces Presentation Of Additional LPCN 1021 Clinical Data At American Society Of Andrology 40th Annual Conference 4/10/2015
Horizon Pharma (HZNP) Receives FDA Fast Track Designation For ACTIMMUNE In The Treatment Of Friedreich's Ataxia 4/10/2015
BioLife Solutions, Inc. (BLFS.OB) CryoStor Cell Preservation Media Embedded In Cardio3 BioSciences' Phase III Clinical Trials Of C-Cure Cell Therapy For Congestive Heart Failure 4/9/2015
Exelixis, Inc. (EXEL)’s Cabozantinib Granted Fast Track Designation By FDA For Advanced Renal Cell Carcinoma 4/9/2015
Edge Therapeutics Banks $72.5 Million for Phase III Brain Hemorrhage Study 4/9/2015
Mesoblast Limited (MSB.AX) Phase 3 Program For Degenerative Disc Disease To Include European Sites After Positive Meeting With European Medicines Agency 4/8/2015
Portola Pharmaceuticals, Inc. Announces New Topline Data From Phase III Annexa-A Trial Part 2: Breakthrough Designated Andexanet Alfa 4/8/2015
GlycoMimetics, Inc. (GLYC) Provides Update On Pfizer (PFE)’s Plans To Initiate Phase 3 Trial With Rivipansel In Mid-2015 4/7/2015
Ocular Therapeutix (OCUL) Reports Topline Clinical Data For Its Second Phase 3 Clinical Trial Evaluating OTX-DP For The Treatment Of Post-Surgical Ocular Inflammation And Pain 4/7/2015
Taxus Cardium (CRXM) Announces Agreement With Dr. Reddy's Laboratories Ltd. (RDY) To Co-Develop, Market & Sell Generx Angiogenic Microvascular Gene Therapy In Certain International Markets 4/7/2015
MedDay Provides Update On Pioneering Pivotal Phase III Study Design In Progressive Multiple Sclerosis 4/7/2015
Cytori Therapeutics, Inc. (CYTX) Granted Orphan Drug Status For Cellular Therapeutic In European Union 4/7/2015
Charleston Laboratories, Inc. Completes Patient Enrollment In A Phase 3 Study Of Lead Product, CL-108 4/6/2015
Icon Bioscience Reports Successful Outcomes Of Phase 3 Study Of IBI-10090, A Novel Sustained Release Drug Being Developed To Treat Inflammation Associated With Cataract Surgery 4/6/2015
Flexion (FLXN) CEO Discusses Pipeline and Jobs 4/3/2015
Public Health Agency of Canada Release: Clinical Trials Prove Canada's VSV-EBOV Ebola Vaccine Safe And Effective 4/2/2015
Heron Therapeutics, Inc. (APPA) Reaches Target Patient Enrollment In MAGIC Phase 3 Study Of SUSTOL 4/2/2015
Thrasos Scores $21M to Complete Phase II THR-184, Expands Renal Portfolio 4/1/2015
Pivotal Pharmacokinetic Study Of Innocoll, Inc. (INNL)'s Xaracoll(R) Supports Use Of 300 Mg Dose For Phase 3 Clinical Studies In Post-Operative Pain 4/1/2015
Receptos (RCPT) Completes Enrollment Of RADIANCE Phase 3 Trial Of Ozanimod In Relapsing Multiple Sclerosis 4/1/2015
Nymox Pharmaceutical (NYMX) Announces Phase 3 BPH Studies 4/1/2015
CEL-SCI (CVM) Reports 3rd Consecutive Month Of Record Patient Enrollment In 2015 For Its Phase III Head And Neck Cancer Trial 4/1/2015
Kala Pharmaceuticals KPI-121 Meets All Primary Endpoints In Phase III For Cataract Surgery 4/1/2015
BioDelivery Sciences International (BDSI) Clonidine Topical Gel Fails Phase III, Shares Plunge 3/31/2015
Emmaus Life Sciences To Present Phase 3 Sickle Cell Disease Clinical Trial Data 3/31/2015
PAION AG Announces Initiation Of U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Colonoscopy 3/31/2015
GW Pharmaceuticals (GWPH) Initiates First Phase 3 Pivotal Trial For Epidiolex In Dravet Syndrome 3/31/2015
Argos Therapeutics, Inc. (ARGS) Reports Fourth Quarter And Year-End 2014 Financial Results 3/31/2015
Achaogen (AKAO) Announces Webcast Providing Update On Development Plan For Plazomicin 3/31/2015
Intra-Cellular Therapies, Inc. Presents The ITI-007 Clinical Development Program At The 15th International Congress On Schizophrenia Research 3/31/2015
Can-Fite BioPharma (CFBI) PhII/III: CF101 Did Not Achieve Primary Endpoint 3/30/2015
GENFIT (ALGFT)'s GFT505 Misses Target in Phase IIB But Hopes to Proceed to Phase III 3/30/2015
Can-Fite BioPharma (CFBI) Files 2014 Annual Report On Form 20-F 3/30/2015
Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3/30/2015
Morphotek Inc. Announces Initiation Of Farletuzumab Study In Patients With First-Relapsed, Platinum-Sensitive Ovarian Cancer With Low Levels Of The Immunosuppressive CA125 Tumor Antigen 3/30/2015
Janssen Research & Development Release: New Study Published In JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time To Relapse In Patients With Schizophrenia 3/30/2015
Sigma-Tau Pharmaceuticals Receives Orphan Drug Designation For EZN-2279 For Treatment Of Adenosine Deaminase--Deficient Severe Combined Immunodeficiency Disease 3/30/2015
Teva (TEVA) Reinforces Leadership Position In CNS With Acquisition Of Auspex Pharmaceuticals (ASPX) 3/30/2015
Cardio3 BioSciences Successfully Completes Futility Analysis Of Lead Cardiac Cell Therapy, C-Cure(R) 3/30/2015
Northwest Biotherapeutics (NWBO) Reports Promising Survival Data In 51 Gbm Patients Treated With Dcvax-L 3/27/2015
Galderma Announces Positive Outcome Of European Decentralised Procedure For Approval Of Soolantra (Ivermectin) Cream 10mg/G For Rosacea Patients 3/27/2015
Results Of Auspex Pharmaceuticals (ASPX)' Phase 3 Registration Trial Of SD-809 To Be Presented At American Academy of Neurology Annual Meeting 3/27/2015
Relypsa (RLYP) Presents Sub-Group Analysis From Phase 3 Study Of Patiromer FOS In Patients With Advanced Chronic Kidney Disease At 2015 National Kidney Foundation Spring Clinical Meeting 3/27/2015
Alnylam (ALNY) Initiates ENDEAVOUR Phase 3 Clinical Trial With Revusiran 3/27/2015
European Medicines Agency Release: Accelerated Assessment Fast-Tracks Lenvima To Benefit Patients With Thyroid Cancer 3/27/2015
NephroGenex (NRX) Announces Data On Acute Kidney Injury At National Kidney Foundation 2015 Spring Clinical Meetings 3/27/2015
Merck & Co. (MRK) Study Halted on Positive Phase III Data 3/26/2015
pSivida Corp (PSDV) Completes Targeted Enrollment Of Phase III Trial Of Medidur For Posterior Uveitis 3/26/2015
Novavax, Inc. (NVAX) Prices Public Offering Of Common Stock 3/26/2015
Cardio3 BioSciences Reports 2014 Financial And Operating Results 3/26/2015
Neothetics Reports Fourth Quarter and Full Year 2014 Financial Results 3/26/2015
Onxeo Expands Livatag International Phase III Clinical Trial "Relive" To 3 New Countries 3/26/2015
Lexicon Pharmaceuticals, Inc. (LXRX) Announces First Patient Screened In Pivotal Phase 3 Clinical Trial Of Sotagliflozin 3/25/2015
Vericel (ASTM) Reports Three-Year Follow-Up Results From Phase 3 SUMMIT Extension Study Of MACI Implant 3/25/2015
TRANSGENE (ENX:TNG) Reports 2014 Financial Results And Outlines Promising Clinical Pipeline 3/25/2015
NephroGenex (NRX) Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2014 3/25/2015
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Initial Payment For RGN-259 U.S. License To ReGenTree Joint Venture 3/25/2015
ThromboGenics NV (TBGNF) Announces Positive Topline Results From OASIS Study 3/24/2015
Mast Therapeutics (MSTX) Reports Fourth Quarter And Full Year 2014 Financial Results 3/24/2015
Aerie Pharmaceuticals, Inc. (AERI) Completes Enrollment In Second Phase 3 Registration Trial (“Rocket 2”) Of Rhopressa, Novel Triple-Action Product To Lower Intraocular Pressure In Patients With Glaucoma 3/24/2015
La Jolla Pharmaceutical Company (LJPC) Announces Initiation Of Phase III Clinical Trial Of LJPC-501 In Catecholamine-Resistant Hypotension 3/24/2015
LFB S.A. Receives Go Ahead From Data Monitoring Committee To Expand The Global PERSEPT Phase 3 Program Of LR769 In Hemophilia A Or B Patients With Inhibitors 3/24/2015
Can-Fite BioPharma (CFBI) Signs Multi-Million Dollar Distribution Agreement For CF101 In Canada With Cipher Pharmaceuticals (DND.TO) 3/23/2015
Cipher Pharmaceuticals (DND.TO) Acquires Canadian Rights To Novel Treatment For Psoriasis And Rheumatoid Arthritis 3/23/2015
Novartis AG (NVS) Presents Cosentyx Two-Year Efficacy And Safety Data Showing Sustainable Effect In Psoriasis Patients 3/23/2015
EXCLUSIVE: Resverlogix Corporation (RVX.TO) CEO Says Experimental Cardiac Drug Holds High Hopes, As Biotech Booms 3/20/2015
AbbVie (ABBV) Elated as Pharmacyclics (PCYC)'s Imbruvica Shines in Combo Trial 3/20/2015
Nektar Therapeutics (NKTR) Cancer Drug Improves Survival But Misses Primary Endpoint, As Watchers Worry 3/20/2015
New Novartis AG (NVS) Data Show More Cosentyx-Treated Psoriasis Patients Achieved Clear Or Almost Clear Skin (PASI 90) Compared To Stelara 3/20/2015
Celgene (CELG) Release: Oral Otezla (Apremilast) Long-Term Safety And Efficacy Data In Patients With Moderate To Severe Plaque Psoriasis Presented At American Academy of Dermatology 3/20/2015
Celgene (CELG) Release: Positive Results From Phase III Study Evaluating Oral Otezla (Apremilast) Or Injectable Etanercept Versus Placebo In Patients With Moderate To Severe Plaque Psoriasis Presented At American Academy of Dermatology 3/20/2015
Intarcia Therapeutics, Inc. And Numab AG Sign Multi-Asset Collaboration To Develop Once-Yearly Therapies In Diabetes, Obesity, and Autoimmune Indications 3/20/2015
Anthera, Inc. Announces $3 Million Research Award From Cystic Fibrosis Foundation Therapeutics, Inc. For Development Of Sollpura - A Novel Enzyme Therapy 3/20/2015
Amgen (AMGN) Submits Application For Investigational LDL Cholesterol-Lowering Medication Repatha (evolocumab) In Japan 3/20/2015
ImmunoCellular Therapeutics, Ltd (IMUC) Chooses PharmaCell As Contract Manufacturing Partner For Its Phase III Program In Europe 3/20/2015
Galderma Laboratories Announces Positive Phase 3 Trial Results Of Investigational Adapalene 0.3%/Benzoyl Peroxide 2.5% (0.3% A/BPO) For The Treatment Of Acne 3/20/2015
Sanofi (SAN.PA) Test Shows Lixisenatide Doesn't Up Cardiovascular Risk 3/19/2015
ImmunoCellular Therapeutics, Ltd (IMUC) Establishes Manufacturing Agreement With Pharmacell B.V. For European Production Of ICT-107 For Phase 3 Registration Trial 3/19/2015
PTC Therapeutics (PTCT) And University of Pennsylvania Collaborate On Orphan Disease Research 3/19/2015
ZS Pharma (ZSPH) To Present Data From Phase 3 Trials Of ZS-9 In Presentations At The National Kidney Foundation 2015 Spring Clinical Meetings 3/19/2015
Scioderm Initiates Phase 3 Registration Trial Of Zorblisatm (SD-101), A Novel Topical Therapy For Patients With Epidermolysis Bullosa 3/19/2015
AstraZeneca PLC (AZN) Two-in-One Lung Drug Succeeds in Phase III Trial 3/19/2015
New Cholesterol Drugs From Amgen (AMGN), Sanofi (SAN.PA), Regeneron (REGN) Cut Heart Risks in Half But Questions Remain 3/18/2015
AstraZeneca PLC (AZN) Announces Positive Phase III Top-Line Results For PT003 From PINNACLE 1 And PINNACLE 2 Studies In COPD 3/18/2015
Lexicon Pharmaceuticals, Inc. (LXRX) And Ipsen (IPN.PA) Expand Their Licensing And Commercialization Agreement For Telotristat Etiprate To Include Canada 3/18/2015
Tenax Therapeutics (TENX) Announces Third Quarter Fiscal Year 2015 Financial Results 3/18/2015
Biogen Idec (BIIB) Will Be Hiring in R&D After Around 20 Employees Leave Following Review 3/17/2015
Pharmacyclics (PCYC) Release: Independent Data Monitoring Committee Unanimously Recommends Unblinding Of IMBRUVICA (Ibrutinib) Phase III Combination HELIOS Trial Based On Interim Analysis Showing Significant Improvement In Progression-Free Survival In Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma 3/17/2015
Sinovac Biotech Ltd. (SVA) Provides Updates On Pipeline Vaccines 3/17/2015
Collegium To Present Xtampza ER Pivotal Phase III Data At The 2015 American Academy Of Pain Medicine Annual Meeting 3/17/2015
The Lancet Publishes CSL Behring's Kcentra Phase III Data 3/17/2015
QIAGEN N.V. (QGEN) Expands Leadership In Liquid Biopsies With New Circulating Tumor Cell Technology For Development Of Companion Diagnostics 3/17/2015
Anavex (AVXL) To Participate In Phase 3 Clinical Trials Panel At AD/PD 2015 3/17/2015
Sanofi (SAN.PA), Regeneron (REGN): 18-Month Results Of ODYSSEY LONG TERM Trial With Praluent (Alirocumab) Published In The New England Journal of Medicine 3/16/2015
Amgen (AMGN) Release: New Detailed Data From Phase 3 Study Show Amgen's Repatha (Evolocumab) In Combination With Statins Reduced LDL-C By 67-76 Percent Compared To Placebo In Japanese Patients With High Cardiovascular Risk And High Cholesterol 3/16/2015
Amgen (AMGN) Publishes Safety Analysis Of Investigational Cholesterol-Lowering Medication Repatha (evolocumab) In The The New England Journal of Medicine 3/16/2015
AcelRx (ACRX) Announces Initiation Of Pivotal Phase 3 Trial For ARX-04 3/16/2015
Anthera Pharmaceuticals, Inc. (ANTH) Announces Completion Of Interim Analysis From Phase 3 Trial With Blisibimod For IgA Nephropathy 3/16/2015
Yisheng Biopharma Co., Ltd. Release: A New Therapeutic Vaccine Successfully Developed Against Rabies 3/16/2015
Provectus Biopharmaceuticals Inc.’ Amended Protocol Of PV-10 For Phase III Study As Treatment For Melanoma Now Available Online 3/16/2015
Mezzion Pharma Commits To Phase 3 Clinical Trials Of Udenafil In Adolescents With A Single Functional Ventricle That Have Undergone Fontan Surgical Palliation 3/16/2015
Medivir AB (MVRBF): New Data On Simeprevir Presented At The Conference Of The Asian Pacific Association For The Study Of The Liver 3/16/2015
Baxter BioScience Corporation (BAX) Announces Positive Phase III Results For BAX 817, Investigational Recombinant Treatment For Hemophila A And B Patients With Inhibitors 3/13/2015
Cytokinetics, Inc. (CYTK) Announces Completion Of Enrollment In COSMIC-HF 3/13/2015
Charleston Laboratories, Inc. And Daiichi Sankyo (4568.t) Announce Completion Of A Pharmacokinetics Study On CL-108 3/12/2015
Provectus Biopharmaceuticals Inc. Updates Market On Business Developments 3/12/2015
Cynapsus Therapeutics (CYNAF) Provides Clinical And Regulatory Update For APL-130277 For The Acute Rescue Of OFF Motor Symptoms Of Parkinson’s Disease 3/12/2015
XBiotech Launches Website And Call Center To Inform Cancer Patients About New Xilonix Therapy And Phase III Clinical Study 3/12/2015
At a Top Notch Facility in SoCal, Amgen (AMGN) Works on Perfecting and Cranking Out Biosimilars 3/11/2015
PharmaEssentia And AOP Orphan Announce Completion Of Recruitment Of Pivotal Phase III Trial PROUD-PV 3/11/2015
Dr. Anita J. Chawla Joins CytRx Corporation (CYTR) Board Of Directors To Add Additional Drug Commercialization Expertise In Oncology 3/11/2015
Takeda (TKPYY) Announces Publication In The Lancet Of A Post Hoc Analysis Of Data From The EXAMINE Cardiovascular Safety Outcomes Trial 3/10/2015
Auris Medical AG (EARS) Announces Completion Of Interim Analysis In Post-Acute Tinnitus Stratum Of TACTT3 Trial With AM-101 3/10/2015
Ocular Therapeutix, Inc. (OCUL) Reports Positive Topline Clinical Data For The First Of Two Phase 3 Clinical Trials Evaluating OTX-DP For The Treatment Of Post-Surgical Ocular Inflammation And Pain 3/10/2015
Trimel Pharmaceuticals (TRL.TO) Announces Natesto Abstract Presentation At The 2015 Endocrine Society Annual Meeting 3/9/2015
Lexicon Pharmaceuticals, Inc. (LXRX) Completes Enrollment In Pivotal Phase 3 Clinical Trial Of Telotristat Etiprate 3/9/2015
Novo Nordisk A/S (NVO) Release: New Data In Adults With Obesity Or Who Are Overweight With Comorbidities Losing At Least 5% Body Weight With Saxenda (liraglutide [rDNA origin] injection) Showed Improvement In Blood Glucose, CV Risk Factors And Quality Of Life Outcomes 3/9/2015
ContraVir Pharmaceuticals To Initiate Pivotal Phase 3 Study Of FV-100 For Prevention Of Shingles-Associated PHN 3/9/2015
CTI BioPharma, Baxter International (BAX)'s Blood Cancer Drug Meets Main Goal in Late-Stage Trial 3/9/2015
Opexa Therapeutics (OPXA) Amends Agreement With Merck Serono And Receives Additional $3 Million Payment To Support Ongoing Development Of Tcelna For Multiple Sclerosis 3/9/2015
R-Tech Ueno: The End Of A Phase 3 Clinical Study And Preliminary Findings From A Phase 3 Of Unoprostone (Development Code UF-021) For Treatment Of Retinitis Pigmentosa 3/9/2015
Orexigen (OREX)'s Failure to Keep a Lid on it Prompts the FDA to Force a Second Study 3/6/2015
BioLineRx Ltd. Announces Underwritten Public Offering Of Its American Depositary Shares 3/6/2015
AEterna Zentaris (AEZS) Announces Pricing Of US$37 Million Public Offering Of Common Shares And Warrants 3/6/2015
CytoTools: European Trials On Diabetic Foot And Ulcus Cruris (Leg Ulcers) On Schedule - Delay In The Market Approval For The Wound Healing Agent Dermapro In India 3/6/2015
EXCLUSIVE: Experimental Cancer Drug From Oncoceutics Could Be Fast-Tracked, Says Exec 3/6/2015
Catalyst Pharmaceuticals (CPRX) Announces FDA Orphan Drug Designation Of Firdapse For Treatment Of Congenital Myasthenic Syndromes 3/5/2015
AOP Orphan Pharmaceuticals AG Announces Progress Of Pivotal Phase 3 Trial PROUD-PV Applying Ropeginterferon ALFA 2B, A Novel, Long-Acting, Mono-Pegylated Interferon For Treatment Of Polycythemia Vera 3/5/2015
Chiasma Announces New Data For Investigational Octreotide Capsules 3/5/2015
Lexicon Pharmaceuticals, Inc. (LXRX) Provides Clinical Pipeline Update And Reports 2014 Fourth Quarter And Full Year Financial Results 3/4/2015
Keryx Biopharmaceuticals (KERX) Announces Publication Of Auryxia (Ferric Citrate) Analysis In Journal Of The American Society Of Nephrology 3/4/2015
CorMedix (CRMD) Provides Multiple Strategic Business Updates 3/4/2015
Drug Approved In Pivotal Studies Using DSG, Inc.’s Fully Electronic Source Data 3/3/2015
Delcath Systems, Inc. (DCTH) Announces Submission Of Phase 3 Trial Results For Publication In A Leading Peer-Reviewed Medical Journal 3/3/2015
Amgen (AMGN) Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 3/3/2015
CEL-SCI (CVM) Reports 2nd Consecutive Month Of Record Patient Enrollment In 2015 For Its Phase III Head And Neck Cancer Trial 3/3/2015
Gilead (GILD)'s Harvoni Achieves 96% Cure Rate in Patients With Hepatitis C and HIV 3/2/2015
Amgen (AMGN) Release: Phase 3 Head-To-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis (Carfilzomib) Over Velcade (Bortezomib) In Patients With Relapsed Multiple Myeloma 3/2/2015
Otsuka Pharmaceutical Co., Ltd. Release: First-Ever Treatment Approved In Canada For Adults Living With ADPKD, A Life-Threatening Kidney Disease 3/2/2015
Portola Pharmaceuticals, Inc. Announces Full Results From Positive Phase 3 ANNEXA-R Study Demonstrating That Andexanet Alfa Rapidly And Significantly Reversed Anticoagulant Effect Of Factor Xa Inhibitor XARELTO 3/2/2015
Dynavax Technologies Corporation (DVAX) Announces Second Independent DSMB Recommendation To Continue Phase 3 Study Of HEPLISAV-B 3/2/2015
CEL-SCI (CVM) Completes Key Milestone With Clearance To Conduct Phase 3 Trial In 21 Countries 3/2/2015
Isis Pharmaceuticals, Inc. (ISIS) Earns $15 Million From GlaxoSmithKline (GSK) for Advancing ISIS-TTR Rx 3/2/2015
Amgen (AMGN)'s Hormone-Imbalance Drug AMG 416 Shows Positive Results in Phase 3 Study 2/27/2015
Gilead (GILD) Announces SVR12 Rates From Phase III Study Evaluating Harvoni For The Treatment Of Chronic Hepatitis C In Patients Co-Infected With HIV 2/27/2015
Argos Therapeutics, Inc. (ARGS) Announces Update On Phase 3 ADAPT Trial To Be Presented During 2015 ASCO Genitourinary Cancers Symposium 2/27/2015
Amgen (AMGN) Receives Positive CHMP Opinion For Use Of Vectibix (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Advanced Colorectal Cancer 2/27/2015